Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSCs for Tolerance in Kidney Transplant
NCT02012153Phase 1Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Dec 2013
- Primary completion
- May 2023
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Provacel in kidney transplant rejection, sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Circulating naïve and memory T cell count (CD45RA/CD45RO) at 12 months, T-cell function by ELISPOT assay in mixed lymphocyte reaction at 12 months and 3 more. Started Dec 2013; status: terminated.
02
Drugs
Provacel
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02012153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02012153.